Press releases

6
Feb 2017
21:30 E.S.T.

FDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S.

Read more
23
Jan 2017
21:30 E.S.T.

Cellectis Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions

Read more
23
Jan 2017
21:30 E.S.T.

Four Prominent Physicians to Join Cellectis Clinical Advisory Board

Read more
4
Jan 2017
21:30 E.S.T.

Cellectis to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 8:00am PT

Read more
3
Jan 2017
21:30 E.S.T.

Cellectis Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN

Read more
16
Dec 2016
21:30 E.S.T.

Cellectis Announces Conference Call To Discuss Recent Recombinant DNA Advisory Committee (RAC) Meeting

Read more
15
Dec 2016
21:30 E.S.T.

Cellectis Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN

Read more
22
Nov 2016
21:30 E.S.T.

Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2016

Read more
21
Nov 2016
21:30 E.S.T.

Cellectis to Participate in Oppenheimer Life Sciences Summit, NY & in Piper Jaffray 28th Annual Health Care Conference, NY

Read more
15
Nov 2016
21:30 E.S.T.

Cellectis Announces Successful cGMP Manufacturing for Second Product Candidate: UCART123

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US